Publications by authors named "Michael Ohene-Nyako"

Opioid overdose deaths have dramatically increased by 781% from 1999 to 2021. In the setting of HIV, opioid drug abuse exacerbates neurotoxic effects of HIV in the brain, as opioids enhance viral replication, promote neuronal dysfunction and injury, and dysregulate an already compromised inflammatory response. Despite the rise in fentanyl abuse and the close association between opioid abuse and HIV infection, the interactive comorbidity between fentanyl abuse and HIV has yet to be examined in vivo.

View Article and Find Full Text PDF

HIV/HIV-1 Tat and morphine independently increase pathologic phosphorylation of TAR DNA binding protein 43 in the striatum. HIV- and opioid-induced pathologic phosphorylation of TAR DNA binding protein 43 may involve enhanced CK2 activity and protein levels.

View Article and Find Full Text PDF
Article Synopsis
  • Despite advancements in HIV treatment, many people living with HIV still face neurocognitive issues, and opioid use disorder (OUD) worsens these problems.
  • Research on transgenic mice examined how HIV-1 Tat and morphine affect the recruitment of immune cells in the brain, specifically looking at the dorsal striatum and hippocampus.
  • The findings indicated that both HIV-1 Tat and morphine increased the recruitment of immune cells, but they did so independently and in different brain regions.
View Article and Find Full Text PDF

The striatum is especially vulnerable to HIV-1 infection, with medium spiny neurons (MSNs) exhibiting marked synaptodendritic damage that can be exacerbated by opioid use disorder. Despite known structural defects in MSNs co-exposed to HIV-1 Tat and opioids, the pathophysiological sequelae of sustained HIV-1 exposure and acute comorbid effects of opioids on dopamine D1 and D2 receptor-expressing (D1 and D2) MSNs are unknown. To address this question, Drd1-tdTomato- or Drd2-eGFP-expressing reporter and conditional HIV-1 Tat transgenic mice were interbred.

View Article and Find Full Text PDF

Opioid use disorder (OUD) is a critical problem that contributes to the spread of HIV and may intrinsically worsen neuroHIV. Despite the advent of combined antiretroviral therapies (cART), about half of persons infected with HIV (PWH) experience cognitive and emotional deficits that can be exacerbated by opioid abuse. HIV-1 Tat is expressed in the central nervous system (CNS) of PWH on cART and is thought to contribute to neuroHIV.

View Article and Find Full Text PDF

Opiate abuse is prevalent among HIV-infected individuals and may exacerbate HIV-associated age-related neurocognitive disorders. However, the extent to which HIV and opiates converge to accelerate pathological traits indicative of brain aging remains unknown. The pathological phospho-isotypes of tau (pSer396, pSer404, pThr205, pSer202, and pThr181) and the tau kinases GSK3β and CDK5/p35 were explored in the striatum, hippocampus, and prefrontal cortex of inducible male and female HIV-1 Tat-transgenic mice, with some receiving escalating doses of morphine for 2 weeks.

View Article and Find Full Text PDF
Article Synopsis
  • Combined antiretroviral therapy effectively lowers viral load in HIV patients but doesn’t prevent brain-related issues like cognitive decline and blood-brain barrier (BBB) disruption, especially in those abusing methamphetamine.
  • A study using HIV-1 transgenic and non-transgenic rats found that HIV-1 proteins decrease BBB tight junction proteins, leading to further damage and inflammation, regardless of methamphetamine use.
  • Both HIV proteins and methamphetamine affect BBB integrity through similar pathways involving NF-κB and MMP-9, highlighting the complex interaction between the virus and substance abuse in brain health.
View Article and Find Full Text PDF

Methamphetamine abuse co-occurring with HIV infection presents neuropathology in brain regions that mediate reward and motivation. A neuronal signaling cascade altered acutely by meth and some HIV-1 proteins is the mitogen-activated protein kinase (MAPK) pathway. It remains unknown if chronic co-exposure to meth and HIV-1 proteins converge on MAPK in vivo.

View Article and Find Full Text PDF

The integrity and function of the gut is impaired in HIV-infected individuals, and gut pathogenesis may play a role in several HIV-associated disorders. Methamphetamine is a popular illicit drug abused by HIV-infected individuals. However, the effect of methamphetamine on the gut and its potential to exacerbate HIV-associated gut pathology is not known.

View Article and Find Full Text PDF